HIV Therapy Effective in Reducing Virus in Multi-Drug Resistant Patients – APhA submits compounding comments to FDA. – (866) 348-2889.
A new HIV therapy demonstrated its efficacy in reducing the virus and boosting immunity in drug-resistant patients, according to a new study published in the New England Journal of Medicine.
The phase 3 trial evaluated the newly-approved treatment, ibalizumab, in 40 patients with advanced, multi-drug-resistant (MDR) HIV infection. A novel therapy, ibalizumab, works by targeting the primary receptor for HIV entry into immune cells, known as CD4 T cells.
For the study, the patients received an intravenous dose of ibalizumab in addition to their failing regimen for 1 week. Then, they received ibalizumab in combination with optimized treatment regimens for 6 months.